Clinical Trial Detail

NCT ID NCT03215706
Title A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

non-small cell lung carcinoma

Therapies

Carboplatin + Cisplatin + Paclitaxel + Pemetrexed

Nivolumab + Ipilimumab

Age Groups: adult senior

Additional content available in CKB BOOST